Follow us on Twitter
This page is updated frequently with new Immune Disease-related patent applications. Subscribe to the Immune Disease RSS feed to automatically get the update: related Immune RSS feeds. RSS updates for this page: Immune Disease RSS
|| List of recent Immune Disease-related patents
| Compounds for use in the treatment of autoimmune inflammatory disease|
And salts thereof is useful in the prophylaxis or treatment of inflammatory bowel disease or other inflammatory autoimmune diseases with similar aetiology involving t-cell proliferation or or function.. .
| Formulation of stable recombinant alpha-fetoprotein conjugated with anti-tumor substance in target-delivery system for treatment of cancer and autoimmune disease|
Disclosed is a stable formulation based on rafp conjugated with drug delivery system of various classes of pharmacological agents such as dactinomycin, cardionolide, and bufadinolide, among others. In another embodiment, the invention discloses a method of producing rafp in a strain of methylotrophic pichia pastoris yeast, allowing the yeast to replicate, and extracting the newly created rafp.
Legrand International Llc
| Substituted anilines as ccr(4) antagonists|
Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
| Stimulation of human meibomian gland function|
Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a pld-inducing compound, such as the cationic amphiphilic drugs (e.g. Azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, igf-1 or an igf-1 analogue (e.g.
The Schepens Eye Research Institute
| Formulations comprising ibrutinib|
Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases.. .
Principia Biopharma Inc.
|Heterocyclic compounds and uses thereof|
The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, egfr (including her), alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, btk, or jak, and the respective pathways.. .
|Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives|
The present invention relates to compositions and methods for cancer treatment comprising compounds of formulae i, ii, and iii. In some aspects, the invention relates to the treatment of b-cell lymphoma or other hematopoietic cancers.
|Establishing the viability of biological samples|
The invention relates to a method, a use and a kit for establishing the viability (ability to live) of biological samples using ageladine a. The invention is advantageously suitable for establishing the viability of biological samples which can otherwise be dyed in an intra-cellular manner by fluorescence dyes other than ageladine a not at all or only with difficulty.
|Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof|
A liposomal formulation for targeting immunotherapy, with synergistic effect in the case of encapsulating an immunosuppressive drug, such as cyclosporine a, and the method of preparing the same. The reduced toxicity and significant reduction of delayed-type hypersensitivity dth) due to extremely reduced dosage, potential therapeutic value in control of chronic transplant rejection, allergies and certain autoimmune diseases, and increased efficacy are some of numerous and significant benefits of the present invention..
|Immunosuppressive blood cells and methods of producing the same|
The present invention refers to a method of producing immunosuppressive blood cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.. .
Systems and methods for extracorporeal blood modification
The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject.
Vaccine and uses thereof
The present disclosure provides immunogenic compositions, such as vaccines, including dna vaccines, and uses thereof, e.g., to suppress or prevent an immune response and/or to treat or prevent an autoimmune disease.. .
Nitrogen-containing bicyclic aromatic heterocyclic compound
[means for solution] it was found that a nitrogen-containing bicyclic heterocyclic compound has the excellent cathepsin s inhibitory effect, thereby completing the invention. The compound of the present invention has the cathepsin s inhibitory effect, and can be used as an agent for preventing and/or treating autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like..
Methods for induction of antigen-specific regulatory t cells
The present invention relates to methods to elicit immature antigen-presenting cells loaded with apoptotic cells or apoptotic bodies. The present invention also relates to methods of obtaining antigen-specific regulatory t cells in vitro or in vivo.
Katholieke Universiteit Leuven
Methods and compositions for sustained immunotherapy
This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of tr1 cells and/or breg cells in an antigen-specific manner and treating autoimmune diseases and disorders in a subject in need thereof.. .
Uti Limited Partnership
A method of diagnosis, prognosis or treatment of an autoimmune disease in a subject wherein the method comprises detecting aquaporin-1 (aqp1), aquaporin-2 (aqp2), aquaporin-5 (aqp5), aquaporin-7 (aqp7) and/or aquaporin-8 (aqp8) autoantibodies in a sample obtained from said subject.. .
This invention provides antibodies that recognize the b cell maturation antigen (bcma) and that bind naïve b cells, plasma cells, and/or memory b cells. The invention further provides methods for depleting naïve b cells, plasma cells, and memory b cells, and for treating b cell-related disorders, including lymphomas and autoimmune diseases..
Biogen Idec Ma Inc.
Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-tnf-α antibody or antigen-binding fragment thereof and at least one anti-il-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a dnl® complex.
Ibc Pharmaceuticals, Inc.
18f-labelled folate/antifolate analogues
The present invention is directed towards new 18f-folate/antifolate analogue radiopharmaceuticals, wherein the phenyl group within folate structures has been replaced by an 18f-heterocycle, their precursors, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.. .
Merck & Cie
Methods of treating inflammatory and autoimmune diseases and disorders
Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder.
Composition for preventing, improving, or treating immune diseases comprising natural extracts as active ingredients
The present invention provides a composition for preventing, improving, or treating th1-mediated immune diseases or th2-mediated immune diseases, an antihistamine composition, and an anti-inflammatory composition. The present invention provides a method for preventing, improving, or treating th1-mediated immune diseases or th2-mediated immune diseases, a method for inhibiting the release of histamine, and a method for preventing, improving, or treating inflammatory disorders.
Korea Food Research Institute
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
The present invention is directed to a pharmaceutical composition including (e.g. For use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
28 kda gst proteins from schistosoma for the use thereof in the treatment of inflammatory autoimmune diseases generating a th1 and/or th17 response
The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kda glutathione s-transferase protein from a schistosome selected from schistosoma haematobium, schistosoma mansoni, schistosoma bovis represented respectively by the sequences seq id no: 1, seq id no: 2 and seq id no: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type th1 and/or th17.. .
Centre Hospitalier Regional Universitaire De Lille
Negatively charged nucleic acid comprising complexes for immunostimulation
The present invention is directed to a pharmaceutical composition including (e.g., for use as an adjuvant) a (negatively charged) nucleic acid comprising complex comprising as a carrier cationic or polycationic compounds (e.g. Peptides, proteins or polymers) and as a cargo at least one nucleic acid (molecule) and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
Popular terms: [SEARCH]
Immune Disease topics: Immune Disease, Autoimmune, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Immune Disorder, Transplant, Autoimmune Disorders, Type 1 Diabetes, Autoimmune Disorder, Proliferative Disorder, Signs And Symptoms, Proliferative, Antagonist, Recurrence
Follow us on Twitter
This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.